Fingolimod impairs inactivated vaccine (CoronaVac)-induced antibody response to SARS-CoV-2 spike protein in persons with multiple sclerosis.

Türkoğlu, Recai; Baliç, Nesrin; Kızılay, Tuğçe; Erol, Ruziye; Akbayır, Ece; Yılmaz, VUSLAT; Tüzün, ERDEM

doi:10.1016/j.msard.2022.103524

Fingolimod impairs inactivated vaccine (CoronaVac)-induced antibody response to SARS-CoV-2 spike protein in persons with multiple sclerosis.

Türkoğlu R., Baliç N., Kızılay T., Erol R., Akbayır E., Yılmaz V., ...Daha Fazla

Multiple sclerosis and related disorders, cilt.58, ss.103524, 2022 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Kısa Makale
Cilt numarası: 58
Basım Tarihi: 2022
Doi Numarası: 10.1016/j.msard.2022.103524
Dergi Adı: Multiple sclerosis and related disorders
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
Sayfa Sayıları: ss.103524
Anahtar Kelimeler: COVID-19, SARS-COV-2, Vaccination, CoronaVac, Multiple sclerosis, Fingolimod
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
İstanbul Üniversitesi Adresli: Evet

Özet

Background: : The impact of disease-modifying treatments on humoral response induced by inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines is understudied. Methods: : We recruited 34 persons with multiple sclerosis (MS) under fingolimod treatment and 25 healthy individuals. Anti-SARS-CoV-2 spike IgG indices were measured by ELISA in sera of participants after CoronaVac vaccinations. Results: : Persons with MS displayed significantly lower antibody levels and seropositivity prevalence. Persons with MS with longer fingolimod treatment durations displayed lower anti-SARS-CoV-2 indices. Conclusion: : Our results support previous findings regarding humoral response impairing effect of fingolimod after vaccinations. Patients under fingolimod treatment may require closer monitoring for COVID-19.